Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.

Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities.

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.